Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced publication of new peer-reviewed research in npj Parkinson's Disease, a ...

ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as ...

New york, USA, Aug. 26, 2026 (GLOBE NEWSWIRE)-- Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight DelveInsight's ...

The analysis also showed that a biomarker of disease severity predicted how quickly patients declined. ... Read More The post Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA ...

Alterity Therapeutics Limited announced that additional analyses from its randomized, double-blind, placebo-controlled ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) were presented at the ...

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.

At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors.

"On the day of the survey, my wife stood up from her chair and walked around the room a little. She didn't have any dizzy ...

Multiple system atrophy (MSA) is an atypical Parkinsonian disorder marked by oligodendroglial α-synucleinopathy and selective neurodegeneration. Although MRI can ...

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterised by a combination of parkinsonism, cerebellar ataxia and autonomic dysfunction. Clinical assessment ...

ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of func ...